ClinicaliQ Trial Snapshot
- Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) — Active Not Recruiting • Phase III • NCT05263934.
- Depemokimab was compared to mepolizumab for treating difficult-to-control EGPA in adults already on standard treatment.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This study aims to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory EGPA receiving SoC therapy. Conditions: Eosinophilic Granulomatosis With Polyangiitis Interventions: Depemokimab, Mepolizumab, Placebo matching mepolizumab, Placebo matching depemokimab Lead Sponsor: GlaxoSmithKline Planned Enrollment: 163 participants